drugset / Trial / NCT07245992
A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
NaSequentialOpen-labelTreatment
Summary
The aim of this study is to evaluate the safety of F8IL10 when administered by intra-articular injection and to determine the maximum tolerated dose (MTD) in order to establish the recommended dose (RD) in patients with Reumatoid Arthritis.
Timeline
- Start
- 2026-01
- Primary completion
- 2028-09-30
- Completion
- 2029-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F8IL10 | Monoclonal antibody | 25 ug | Other |
| Subject | F8IL10 | Monoclonal antibody | 50 ug | Other |
| Subject | F8IL10 | Monoclonal antibody | 100 ug | Other |
| Subject | F8IL10 | Monoclonal antibody | 400 ug | Other |
| Subject | F8IL10 | Monoclonal antibody | 700 ug | Other |
| Subject | F8IL10 | Monoclonal antibody | 1000 ug | Other |